ATARA BIOTHERAPEUTICS INC (ATRA) Stock Overview
USA - NASDAQ:ATRA - US0465132068 - Common Stock
ATRA Key Statistics, Chart & Performance
The current stock price of ATRA is 13.83 USD. In the past month the price increased by 11.82%. In the past year, price increased by 71.02%.
ATRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.64 | 386.06B | ||
| AMGN | AMGEN INC | 12.43 | 145.99B | ||
| GILD | GILEAD SCIENCES INC | 14.34 | 137.72B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.54 | 97.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.93B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.17 | 58.88B | ||
| ARGX | ARGENX SE - ADR | 76.71 | 43.52B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.75 | 39.08B | ||
| INSM | INSMED INC | N/A | 28.66B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.58B | ||
| NTRA | NATERA INC | N/A | 22.46B | ||
| BIIB | BIOGEN INC | 8.47 | 19.89B |
Related stock screener links
About ATRA
Company Profile
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in Thousand Oaks, California and currently employs 38 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Company Info
ATARA BIOTHERAPEUTICS INC
1280 Rancho Conejo Blvd
Thousand Oaks CALIFORNIA 94080 US
CEO: Pascal Touchon
Employees: 153
Phone: 18056234211
ATARA BIOTHERAPEUTICS INC / ATRA FAQ
What is the stock price of ATARA BIOTHERAPEUTICS INC today?
The current stock price of ATRA is 13.83 USD. The price decreased by -3.02% in the last trading session.
What is the ticker symbol for ATARA BIOTHERAPEUTICS INC stock?
The exchange symbol of ATARA BIOTHERAPEUTICS INC is ATRA and it is listed on the Nasdaq exchange.
On which exchange is ATRA stock listed?
ATRA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ATARA BIOTHERAPEUTICS INC stock?
10 analysts have analysed ATRA and the average price target is 16.83 USD. This implies a price increase of 21.69% is expected in the next year compared to the current price of 13.83. Check the ATARA BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ATARA BIOTHERAPEUTICS INC worth?
ATARA BIOTHERAPEUTICS INC (ATRA) has a market capitalization of 97.09M USD. This makes ATRA a Micro Cap stock.
How many employees does ATARA BIOTHERAPEUTICS INC have?
ATARA BIOTHERAPEUTICS INC (ATRA) currently has 153 employees.
What are the support and resistance levels for ATARA BIOTHERAPEUTICS INC (ATRA) stock?
ATARA BIOTHERAPEUTICS INC (ATRA) has a support level at 12.04. Check the full technical report for a detailed analysis of ATRA support and resistance levels.
Is ATARA BIOTHERAPEUTICS INC (ATRA) expected to grow?
The Revenue of ATARA BIOTHERAPEUTICS INC (ATRA) is expected to grow by 3.31% in the next year. Check the estimates tab for more information on the ATRA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ATARA BIOTHERAPEUTICS INC (ATRA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ATRA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ATRA, evaluating the profitability, health, valuation and growth aspects
- ATARA BIOTHERAPEUTICS INC (ATRA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ATARA BIOTHERAPEUTICS INC (ATRA) Sales and EPS estimates to see what analysts future expectations are.
- ATARA BIOTHERAPEUTICS INC (ATRA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ATARA BIOTHERAPEUTICS INC (ATRA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ATARA BIOTHERAPEUTICS INC (ATRA) Stock Chart to make your own analysis
- ATARA BIOTHERAPEUTICS INC (ATRA) Latest news and press-releases to stay up to date.
Does ATARA BIOTHERAPEUTICS INC (ATRA) stock pay dividends?
ATRA does not pay a dividend.
When does ATARA BIOTHERAPEUTICS INC (ATRA) report earnings?
ATARA BIOTHERAPEUTICS INC (ATRA) will report earnings on 2025-11-10.
What is the Price/Earnings (PE) ratio of ATARA BIOTHERAPEUTICS INC (ATRA)?
ATARA BIOTHERAPEUTICS INC (ATRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.43).
What is the Short Interest ratio of ATARA BIOTHERAPEUTICS INC (ATRA) stock?
The outstanding short interest for ATARA BIOTHERAPEUTICS INC (ATRA) is 3.14% of its float. Check the ownership tab for more information on the ATRA short interest.
ATRA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ATRA. When comparing the yearly performance of all stocks, ATRA is one of the better performing stocks in the market, outperforming 94.43% of all stocks.
ATRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ATRA. ATRA has a medium profitability rating, but doesn't score so well on its financial health evaluation.
ATRA Financial Highlights
Over the last trailing twelve months ATRA reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 98.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.07% | ||
| ROA | 15.7% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ATRA Forecast & Estimates
10 analysts have analysed ATRA and the average price target is 16.83 USD. This implies a price increase of 21.69% is expected in the next year compared to the current price of 13.83.
For the next year, analysts expect an EPS growth of 91.7% and a revenue growth 3.31% for ATRA